In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Session Poster Session 2

Speaker Subodh Verma

Event : ESC Congress 2018

  • Topic : cardiovascular pharmacology
  • Sub-topic : Anti-Diabetic Pharmacotherapy
  • Session type : Poster Session

Authors : S Verma (Toronto,CA), DC Mazer (Toronto,CA), DL Bhatt (Boston,US), SR Raj (Nashville,US), AT Yan (Toronto,CA), A Verma (Toronto,CA), E Ferrannini (Pisa,IT), G Simons (Ingelheim,DE), J Lee (Ingelheim,DE), B Zinman (Toronto,CA), JT George (Ingelheim,DE), D Fitchett (Toronto,CA)

Authors:
S. Verma1 , D.C. Mazer2 , D.L. Bhatt3 , S.R. Raj4 , A.T. Yan5 , A. Verma1 , E. Ferrannini6 , G. Simons7 , J. Lee7 , B. Zinman8 , J.T. George7 , D. Fitchett5 , 1St Michael's Hospital, Division of Cardiac Surgery, University of Toronto - Toronto - Canada , 2St Michael's Hospital, Department of Anesthesia, University of Toronto - Toronto - Canada , 3Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School - Boston - United States of America , 4Vanderbilt University, Division of Clinical Pharmacology - Nashville - United States of America , 5St Michael's Hospital, Division of Cardiology, University of Toronto - Toronto - Canada , 6University of Pisa School of Medicine - Pisa - Italy , 7Boehringer Ingelheim International GmbH - Ingelheim - Germany , 8Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto - Toronto - Canada ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 399

Background: In patients with type 2 diabetes, left ventricular hypertrophy (LVH) is an established predictor of cardiovascular (CV) risk; whether glucose-lowering therapy reduces CV events in this high-risk group remains unknown. In the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of 3-point MACE (composite of CV death, MI, or stroke) (primary outcome) by 14%, CV death by 38% and all-cause mortality by 35% vs placebo in patients with type 2 diabetes and established CV disease. In this post hoc analysis, we investigated the effects of empagliflozin on CV events and mortality in patients with ECG LVH.

Methods: A total of 7020 patients with type 2 diabetes and established CV disease received study drug. Patients without a baseline ECG, an uninterpretable ECG, or who took study drug prior to baseline ECG were excluded from the analysis.

Results: Of 5973 patients included in this analysis, 140 had ECG LVH at baseline. The incidence rate for CV death (per 1000 patient-years) was 78.9 vs 19.1 in placebo-treated patients with vs without LVH and 32.1 vs 11.6 in empagliflozin-treated patients with vs without LVH. The incidence rates for 3-point MACE and all-cause mortality were also approximately 4 times higher in those with than without LVH. Empagliflozin reduced CV events to a greater extent in patients with LVH at baseline. The hazard ratios (95% CI) for 3-point-MACE were 0.39 (0.19, 0.81) in patients with LVH vs 0.89 (0.76, 1.05) in those without LVH (p-value for interaction = 0.0295). The hazard ratios for CV death were 0.40 (0.16, 1.01) in patients with LVH vs 0.60 (0.47, 0.78) in patients without LVH (p-value for interaction = 0.4034). The hazard ratios for all-cause death were 0.32 (0.13, 0.78) in patients with LVH vs 0.67 (0.55, 0.83) in patients without LVH (p-value for interaction = 0.1126). The absolute risk reductions with empagliflozin vs placebo were greater because both the event rates and the relative risk reductions were higher in patients with vs without LVH.

Conclusions: In patients with type 2 diabetes and CV disease, LVH is associated with significantly higher rates of CV events and mortality. In the EMPA-REG OUTCOME trial, the magnitude of CV benefit with empagliflozin appeared large in the subgroup with LVH.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are